Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.20.2
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Segment Reporting Information [Line Items]        
Total revenues $ 18,385 $ 21,906 $ 48,023 $ 49,808
Cost of product revenue 3,642 5,067 7,882 12,230
Research and development 12,010 8,711 33,830 25,000
Selling, general and administrative 8,797 7,869 26,307 24,180
Total costs and operating expenses 24,449 21,647 68,019 61,410
Income (loss) from operations (6,064) 259 (19,996) (11,602)
Depreciation and amortization     (1,403) (1,118)
Income (loss) before income taxes (6,075) 336 (19,759) (11,288)
Stock-based compensation 1,984 1,732 6,092 5,783
Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 13,005 20,424 31,385 41,100
Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 5,380 1,482 16,638 8,708
Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Total revenues 18,385 21,906 48,023 49,808
Cost of product revenue 3,642 5,067 7,882 12,230
Research and development 11,617 8,393 32,725 24,141
Selling, general and administrative 3,190 2,727 9,123 8,267
Total costs and operating expenses 18,449 16,187 49,730 44,638
Income (loss) from operations (64) 5,719 (1,707) 5,170
Stock-based compensation 1,984 1,732 6,092 5,783
Operating Segments [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 13,005 20,424 31,385 41,100
Cost of product revenue 3,642 5,067 7,882 12,230
Research and development 5,184 5,313 15,877 14,889
Selling, general and administrative 2,675 2,037 7,395 6,499
Total costs and operating expenses 11,501 12,417 31,154 33,618
Income (loss) from operations 1,504 8,007 231 7,482
Stock-based compensation 839 736 2,335 1,973
Operating Segments [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 5,380 1,482 16,638 8,708
Cost of product revenue 0 0 0 0
Research and development 6,433 3,080 16,848 9,252
Selling, general and administrative 515 690 1,728 1,768
Total costs and operating expenses 6,948 3,770 18,576 11,020
Income (loss) from operations (1,568) (2,288) (1,938) (2,312)
Stock-based compensation 132 225 625 563
Corporate [Member]        
Segment Reporting Information [Line Items]        
Total costs and operating expenses (5,483) (4,912) (16,526) (15,185)
Depreciation and amortization (528) (471) (1,526) (1,273)
Income (loss) before income taxes (6,075) 336 (19,759) (11,288)
Stock-based compensation 1,013 771 3,132 3,247
Product Revenue [Member]        
Segment Reporting Information [Line Items]        
Total revenues 8,401 10,351 18,005 24,588
Product Revenue [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 8,401 10,351 18,005 24,588
Product Revenue [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 0 0 0 0
Product Revenue [Member] | Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Total revenues 8,401 10,351 18,005 24,588
Product Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 8,401 10,351 18,005 24,588
Research and Development Revenue [Member]        
Segment Reporting Information [Line Items]        
Total revenues 9,984 11,555 30,018 25,220
Research and Development Revenue [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 4,604 10,073 13,380 16,512
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 5,380 1,482 16,638 8,708
Research and Development Revenue [Member] | Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Total revenues 9,984 11,555 30,018 25,220
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 4,604 10,073 13,380 16,512
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues $ 5,380 $ 1,482 $ 16,638 $ 8,708